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Abstract
In cancer translational research, increasing effort is devoted to the study of the com-
bined effect of two drugs when they are administered simultaneously. In this paper,
we introduce a new approach to estimate the part of the effect of the two drugs due
to the interaction of the compounds, i.e. which is due to synergistic or antagonistic
effects of the two drugs, compared to a reference value representing the condition
when the combined compounds do not interact, called zero-interaction. We describe
an in-vitro cell viability experiment as a random experiment, by interpreting cell
viability as the probability of a cell in the experiment to be viable after treatment,
and including information related to different exposure conditions. We propose
a flexible Bayesian spline regression framework for modelling the viability surface
of two drugs combined as a function of the concentrations. Since the proposed
approach is based on a statistical model, it allows to include replicates of the ex-
periments, to evaluate the uncertainty of the estimates, and to perform prediction.
We test the model fit and prediction performance on a simulation study, and on an
ovarian cancer cell dataset. Posterior estimates of the zero-interaction level and of
the synergy term, obtained via adaptive MCMC algorithms, are used to compute
interpretable measures of efficacy of the combined experiment, including relative
volume under the surface (rVUS) measures to summarise the zero-interaction and
synergy terms and a bi-variate alternative to the well-known EC50 measure.
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1 Introduction
Drugs are usually administered to cancer patients following a protocol designed
for the specific cancer. When a drug reveals to be no longer effective, due to the
development of resistance, its concentration might be increased, or the drug itself
might be changed. The effectiveness of a drug against a particular malignancy
can, in some cases, be estimated in pre-clinical in-vitro concentration-response ex-
periments, such as viability assays or other cell count assays, in a set-up called
cancer drug sensitivity screening (CDSS). Primary cancer cells, derived from pa-
tient material, or cell-lines derived from patients, are treated with drugs in-vitro,
thus providing an estimate of the number of viable cells after exposure to treat-
ment. These studies are often performed for one drug at a time (monotherapy) in
high-throughput screenings. The data produced by these assays present different
sources of variability, related to biological factors such as cell growth or the drug’s
mechanism of action, in addition to measurement errors. The mitigation of such
variability components is difficult to tackle, and often viability data are analysed
by simply fitting a parametric concentration-response curve to the data, after re-
moval of background noise elements. The most commonly used function for this
purpose is the Hill equation [Hill, 1910], or median-effect law [Chou and Talalay,
1984], also called four-parameter log-logistic (4LL) curve:
f(x|m,λ) = a+ (b− a)
(
1 + 10λ(log10(x)−m))
)−1
, x ∈ R+, (1)
where a and b are the lower and upper asymptotes of the curve, respectively.
The parameter λ represents the steepness of the fitted curve: positive values of
λ are associated with cell survival (viability). The parameter m is the popular
log10-transformed Half-Maximal Effective Concentration (or EC50), providing the
amount of compound needed to observe a response equal to 50%.
Many studies have explored the possibility of testing multiple drugs simultane-
ously in-vitro, with the aim of understanding the interactions between them and
the consequent effect on cancer progression. An interaction can strengthen the
effect (synergistic) of each drug, or weaken it (antagonistic) [for recent studies,
see e.g. O’Neil et al., 2016, Kashif et al., 2017]. The synergistic or antagonistic
effect of a combination of drugs is defined in relation to a non-interaction base-
line, representing the condition in which the two drugs do not interact with each
other. This condition is not testable experimentally, so that hypotheses need to
be made, based on appropriate mathematical definitions. Cell viability observa-
tions from monotherapy experiments are used to define the zero-interaction level.
Many different models have been proposed in the literature, in particular Loewe
and Muischnek [1926], Loewe [1953], Bliss [1939], Webb [1963], Chou and Talalay
[1984], Berenbaum [1989], Tallarida et al. [1989], Greco et al. [1995]; see also the
review Fouquier and Guedj [2015]. More recently, the interest has moved towards
trying to understand, by means of statistical methods, how reliable the interaction
assessments are. Some studies are based on viability experiments, as in Tallarida
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[1992], Yadav et al. [2015]. Others have proposed model-based analysis [Boik et al.,
2008, Lee and Kong, 2009, Whitehead et al., 2013, Hautaniemi et al., 2018], and
some such as Johnstone et al. [2016], Hennessey et al. [2010], Li et al. [2007] are
set in a Bayesian framework.
This paper presents a novel model-based approach to the study of drug-drug in-
teraction, modelling the drug combination surface using a flexible Bayesian spline
regression approach. The viability surface, depending on the concentrations of
the two drugs, is described by a simple stochastic model, which allows to dis-
criminate between the non-interaction and the interaction parts of the viability.
Our modelling approach allows for posterior inference on both the monotherapy
concentration-response curves (included in the non-interaction part), and the inter-
action part. Importantly, we are able to quantify the uncertainty of our Bayesian
estimates. To the best of our knowledge, this is the first time that a similar prob-
abilistic description of the viability experiment is proposed in the literature.
The main model is introduced in Section 2.1, by providing a probabilistic in-
terpretation of the viability experiment, and by defining both the zero-interaction
and the interaction terms. Section 3 proposes a performance evaluation of the
new methodology with an extensive simulation, as well as in an in-house produced
ovarian cancer dataset. Section 4 concludes.
2 Modelling Responses from Combined Exper-
iments
In a viability combination experiment, two compounds at concentrations x1i, for
i = 0, . . . , n1, and x2j , for j = 0, . . . , n2, are dispensed. Every experiment is
repeated nrep times at the selected concentrations. We will sometimes write x1 =
(x10, . . . , x1n1) and x2 = (x20, . . . , x2n2). Specifically, i = 0 and j = 0 correspond
to the absence of the compounds, i.e. x10 = 0 and x20 = 0. The response is
measured as the fluorescence (or luminescence) level F rij , assumed proportional to
the number of viable cells present at time of observation, denoted by Zrij ∈ N,
for (i, j) as above and r = 1, . . . , nrep. The proportionality constant (i.e., the
fluorescence of a single viable cell) is assumed to be the same in each experimental
condition, so that Zrij represents the measured viable cell count. Given the pair
of indices (i, j), consider the well characterized by the concentrations (x1i, x2j).
Let N r0,ij be the total number of cells - viable or not - present in this well at the
time of measuring, and indicate with pij ∈ (0, 1) the probability that a cell is
viable in the well, independently of the experimental replicate. This probability
can be estimated using the cell counts via the ratio
Zrij
Nr0,ij
, for i = 0, . . . , n1 and
j = 0, . . . , n2. However, in practice the value of N r0,ij is not known, and it is
estimated using specific control wells, obtaining an estimate N˜ r0 by averaging the
control counts. Due to the inherited variability of the estimate N˜ r0 , the so-obtained
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random variables Y rij =
Zrij
N˜r0
can be interpreted as a noisy version of the underlying
probabilities of success pij , subject to an error term dependent on both biological
and experimental factors. For this reason, we model the observed quantities yrij as
follows:
y1ij , . . . , y
nrep
ij ∼ N(pij , σ2 ), i = 0, . . . , n1, and j = 0, . . . , n2, (2)
where σ2 in a homoschedastic variance term. Notice how this model accommodates
observations which lie outside the range (0, 1), which is the range of admissible
values for the mean term pij . This is a desired feature of our model, since the
observations yrij often lie outside the range (0, 1). In fact, this can be observed as
an effect of normalization with respect to controls.
In the current literature on drug-drug interaction quantification, the responses
are assumed to be influenced by two main elements: a zero-interaction term de-
scribing the impact of the individual drugs on the outcome as if they were not
interacting, and a residual term describing the amount of interaction present in
the experiment. The first term is usually obtained by describing mathematical
models suitable for the experiment under study, while the second - the interaction
term - is quantified as the residual of the observations and the expected values un-
der the chosen zero-interaction model. Therefore, it is clear how the definition of
the zero-interaction model plays a crucial role in the interpretation and estimation
of the interaction between two drugs. In the next two sections, we provide details
on these two terms and show how they can be included jointly in a Bayesian model.
2.1 Models for the Zero-Interaction Term
We now move on to modelling the mean viability probability pij . We start by
providing insights on the mechanism of action of the combination of compounds.
The drugs used in the experiment can act on the same sites of the targeted molecule,
or affect the same signaling pathway, and therefore can be consideredmutually non-
exclusive. If they act on different sites or pathways, are instead called mutually
exclusive. In the latter scenario, the Bliss independence model [Bliss, 1939] is
an appropriate model for zero-interaction [Fitzgerald et al., 2006]. This model is
introduced more rigorously, by defining the following event:
Aij := “a cell survives both drugs at concentrations (x1i, x2j) in the combined
experiment”.
Referring to equation (2), our interest lies in modelling pij = P(Aij). It is useful
to define the single-drug events:
D1i := “a cell survives the first drug at concentration x1i in the combined exper-
iment”;
D2j := “ ‘a cell survives the second drug at concentration x2j in the combined
experiment”.
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We have that pij = P(Aij) = P(D1i ∩ D2j). In order to describe P(Aij), we intro-
duce the zero-interaction component P0(Aij) in the analysis. Then, the difference
between P(Aij) and P0(Aij) is the interaction term, i.e. the quantity representing
the amount of information in the combined experiment that is not explained by
the zero-interaction model: ∆ij := pij − P0(Aij).
Following Bliss [1939], we interpret the zero-interaction of the two compounds
as probabilistic independence of the single-drug events, so that P0(Aij) = P(D1i)P(D2j).
We point out that the events D1i and D2j are defined in the combined experiment,
and their probabilities can be estimated from monotherapy experiments. We take
this approach in the present paper, and model P(D1i) and P(D2j) by assuming
(1) after setting the boundaries (a, b) = (0, 1). The resulting parametric func-
tion is the 2-parameter log-logistic curve (2LL). This approach is analogous to
the zero-interaction potency (ZIP) model introduced by Yadav et al. [2015]. We
write p0ij := P0(Aij) = f(x1i|θ1)f(x2j |θ2), where θ1 = (m1, λ1) and θ2 = (m2, λ2).
Notice that θ1 and θ2 are assumed to be constant across replicates and different
concentrations.
Alternative specifications for the zero-interaction term exist in the literature.
Very popular are the highest single agent (HSA) model by Berenbaum [1989] and
the Loewe additivity model by Loewe [1953]. The first one is based on the idea that
the zero-interaction effect is equal to the most effective compound taken alone:
yHSAij = max{y1i, y2j}.
It can be easily shown that yHSAij ≤ p0ij , where p0ij is the Bliss zero-interaction term
just introduced [see also Tang et al., 2015].
When the two compounds have a similar mechanism of action and are mutually
non-exclusive, the Loewe additive model is often used [Fitzgerald et al., 2006]. This
situation can be interpreted as the drugs acting on the same site of the targeted
molecule, or along the same pathway. Therefore, it would be sensible to assume
that the two compounds should compensate each other when varying their concen-
trations. Under this assumption, and further assuming that a functional form is
available to describe the monotherapy experiments f1(x1i), f2(x2j), then the zero-
interaction response yLoeweij is defined as the solution of the following equation:
x1i
f−11 (yLoeweij )
+
x2j
f−12 (yLoeweij )
= 1, (3)
for each pair of doses (x1i, x2j), with i = 1, . . . , n1 and j = 1, . . . , n2. The functions
f1 and f2 are the monotherapy dose-response curves for the compounds tested, and
are often assumed to be of form (1). Synergism or antagonism are detected when
the value of the left term in (3) is smaller or greater than 1, respectively.
2.2 The Interaction Term
Next we model the interaction term ∆ij . Because pij = p0ij + ∆ij ∈ (0, 1), and
the co-domain of the 2LL curve is (0, 1), so that p0ij ∈ (0, 1) for any value of
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(θ1, θ2), the range of admissible values for the interaction term ∆ij is the inter-
val I∆ij := (−p0ij , 1 − p0ij). While monotonicity in concentration is assumed for
the monotherapy response curves and for the zero-interaction surface, this is too
restrictive for the interaction term ∆ij , as we want to be able to capture both
synergistic and antagonistic behaviours. To allow higher flexibility, we use natural
cubic splines to model the interaction between the compounds [see de Boor, 2001,
for a review]. The use of splines in the analysis of drug combination surfaces has
been proposed in Wheeler [2017], where an approach based on Gaussian processes is
pursued, but without differentiating between the zero-interaction and the interac-
tion terms. In this paper, we specify a tensor spline obtained as the cross-product
of two univariate cubic B-splines, each defined over a set of K1 and K2 equally
spaced knots to cover the log10 concentration ranges of x1 and x2, respectively.
We use truncated power polynomials to produce the B-spline basis, following Eil-
ers and Marx [2010]. The spline coefficients are parameterized by a matrix C, for
which a suitable prior distribution is chosen. We include the tensor-spline values
for each combination in a regression setting, with the use of additional linear coef-
ficients γ0, γ1, and γ2. These coefficients do not have a direct interpretation in the
model description, but allow for more flexibility in the posterior inference for the
interaction term ∆ij :
Bij = γ0 + γ1x1i + γ2x2j + B(x1i, x2j),
B(x1i, x2j) =
∑
l,m
ClmBl(x1i)Bm(x2j),
with Bl(x) a univariate cubic spline at knot l and evaluated at x ∈ R. We cannot
merely assume ∆ij = Bij , because Bij ∈ R, while ∆ij ∈ I∆ij , for each (i, j). There-
fore, we introduce a suitable link function g : R → I∆ij . Several different choices
for g can be considered, for instance a truncation term or a linear transformation.
Here, we use the following:
g(Bij) = −p0ij(1 + eb1Bij )−1 + (1− p0ij)(1 + e−b2Bij )−1.
The link function g is applied to each spline term and pair of concentrations tested,
yielding ∆ij = g(Bij)I0(i, j), where I0(i, j) = 0 if i = 0 or j = 0, and I0(i, j) = 1
otherwise. This indicator prevents any interaction in the absence of either of the
compounds (or at such a low level that we do not expect any compound activation),
i.e. for x10 or x20. Two extra parameters (b1, b2) are introduced with g, regulating
the behaviour of the transformation. In particular, by imposing that b1, b2 > 0,
we can ensure that g is monotonically non-decreasing and surjective. Observe how
imposing b1 = b2 = b > 0 yields pij = (1 + e−bBij )−1, corresponding to a tensor-
product spline logistic regression model, losing the interpretability of the terms p0ij
and ∆ij . Therefore, we will assume that b1 6= b2, a condition that is verified by
assuming, for instance, that b1 and b2 are continuous random variables a priori.
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2.3 Full Bayesian Model for Drug Interaction
Summarising, the proposed model has the form:
Y rij = p
0
ij + ∆ij + 
r
ij , {rij} i.i.d.∼ N(0, σ2ij),
p0ij = f(x1i|m1, λ1)f(x2j |m2, λ) = (1 + 10λ1(log10(x1i)−m1))−1(1 + 10λ2(log10(x2j)−m2))−1,
∆ij = g(Bij)I0(i, j), g(Bij) = −p0ij(1 + eb1Bij )−1 + (1− p0ij)(1 + e−b2Bij )−1,
Bij = γ0 + γ1x1i + γ2x2j + B(x1i, x2j),
B(x1i, x2j) =
∑
l,m
ClmBl(x1i)Bm(x2j), (4)
C ∼ Matrix-NK1,K2 (0,ΨK1 ,ΨK2),
ψ|αψ, βψ ∼ Γ(αψ, βψ), ψ ∈ {λ1, λ2, b1, b2}
φ|σ2φ ∼ N(0, σ2φ), φ ∈ {m1,m2, γ0, γ1, γ2},
σ2m1 , σ
2
m2 , σ
2
γ0 , σ
2
γ1 , σ
2
γ2 , σ
2
ij ∼ piσ2 ,
for i = 0, . . . , n1, j = 0, . . . , n2, and r = 1, . . . , nrep. The last four lines of (4)
describe our prior distributions. The matrix of spline coefficients C is a priori
distributed as a matrix-variate normal of dimensions (K1,K2) centred on the zero
matrix 0. Second order difference matrices ΨK1 and ΨK2 are used to penalise the
jumps at the knot values of the tensor product spline. We assume vague Gamma
prior distributions for the parameters λ1, λ2, b1, and b2 (mean = 1, variance =
100), and normal prior distributions with zero mean and variance parameter σ2m1
and σ2m2 for m1 and m2. We explored a range of possibilities for the hyper-priors
on the variability parameters σ2φ, denoted in the last line of (4) as piσ2 : half-Cauchy
distribution HC(h), h ∈ {0.1, 0.5, 1, 5, 10}, or inverse-gamma distribution IG(α, β),
(α, β) ∈ {(3, 2), (0.1, 0.1), (0.05, 0.05), (0.025, 0.025), (0.01, 0.01)}. We point out
that the choice of assigning the same hyper-prior to all the variance terms σ2φ,
for φ as in (4), is motivated by easing the computational burden, and that other
options can be easily explored (e.g., including prior information about the vari-
ability of the parameters φ). Finally, the variability of the error terms {rij} is
assigned a prior distribution piσ2ij , in accordance with the choices specified for piσ2 ,
restricting our analysis to the homoscedastic case, for which σ2ij = σ
2
 for each
(i, j). This framework is easily extendible to recover the heteroscedastic model de-
picted in (4), without significantly increasing the computational burden. However,
the heteroscedastic model would require a more detailed prior elicitation analysis,
representing a possibility for further extensions of the proposed framework.
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3 Applications
3.1 Computational details
The posterior estimates of the parameters of the model are obtained by MCMC
sampling. Due to the presence of several non-conjugate parameters in the model,
we resort to an adaptive version of the Metropolis-within-Gibbs algorithm [see
Griffin and Stephens, 2013]. The class of adaptive MCMC methods involves using
the samples obtained during the sweeps of the Gibbs sampler in order to produce
a candidate for the current Metropolis-Hastings step. In particular, the proposal
density of a parameter of interest, say q(θcurr, θ′) - where θ′ represents a new
value of the parameter θ, and θcurr is the value at the current iteration - can be
defined to include additional information deriving from the values of θ visited so
far. A description of the algorithm is provided in Section 2 of the Supplementary
Materials.
3.2 Simulation study
In order to provide a performance evaluation of the proposed model, we simulated
datasets with different features. In particular, the mean surface of the true model
is split into two components, as to represent the zero-interaction term p0 and the
interaction term ∆, and it is characterised by the same error term σ2 , for each
(i, j), as follows:
Y rij |pij , σ2 , ν ind∼ F(·|pij , σ2 , ν), r = 1, . . . , nrep,
pij = p
0
ij + ∆ij ,
p0ij = Φ
(
2µ− (x1i, x2j),µ = (0, 5),Σ =
[
5 0
0 5
])
,
σ2 = 0.05
2,
where the concentrations are log10(x1) = (−∞,−4, . . . , 4, 5) and log10(x2) =
(−∞,−3.5, . . . , 3.5, 5.5). For computational reasons, the smallest concentration
will be replaced by a value equal to -2 times in log10-scale from the next minimum
concentration when needed in the algorithm. The term F(·|pij , σ2 , ν) represents the
sampling model chosen for the simulations, which depends on the mean term pij at
each concentration pair (x1i, x2j), the error σ2 , and a set of additional parameters
ν. In particular, we adopt a normal distribution, s.t. F(·|pij , σ2 , ν) = N(·|pij , σ2 ),
for which no additional parameters are needed, or a location-scale t-Student dis-
tribution with ν = 5 degrees of freedom, s.t. F(·|pij , σ2 , ν) = t5(·|pij , σ2 ). The
function Φ((x, y),µ,Σ) represents the c.d.f. of the bi-variate normal distribution
with mean µ and covariance matrix Σ, evaluated at (x, y). The zero-interaction
term reflects specific monotherapy behaviours at the boundaries, for which one
drug is more effective than the other. We assess the efficacy of the individual drugs
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via the drug sensitivity scores (DSS) [Yadav et al., 2014]. This quantity is a nor-
malized area under the concentration-response curve, taking into account the range
of the data, and interpretable as the percentage of efficacy of the drug tested. In
order to compute the DSS scores for the individual compounds, we first estimate
the parameters of the concentration-response curves by fitting a 2LL regression to
each monotherapy set of points via the drm function of the R package drc, yield-
ing (mˆ1, λˆ1) = (0, 0.33) and (mˆ2, λˆ2) = (4.96, 0.31), respectively. These estimates
were used to obtain DSS scores of 64.02 and 13.25, respectively, indicating higher
efficacy of the first drug. The interaction term ∆ was specified in three different
ways throughout the simulation study:
• ∆(1)ij = 0, ∀(i, j),
• ∆(2)ij = Φ
(
(x1i, x2j),µ = (5, 5),Σ =
[
10 0
0 10
])
,
• ∆(3)ij = 0.5
[
Φ
(
(x1i, x2j),µ1,Σ1 =
[
1 0
0 1
])
−Φ
(
2µ2 − (x1i, x2j),µ2,Σ2 =
[
1 0
0 1
])]
,
where µ1 = (1, 1) and µ2 = −µ1. We considered datasets with nrep ∈ {1, 3, 5, 10}.
We fit model (4) to each simulated dataset for every choice of prior distribution piσ2 ,
as mentioned in Section 2.3. The adaptive MCMC algorithm is run for 100.000
iterations, of which the first half is discarded as burn-in period, and the second
half is thinned every 10-th iteration, yielding a final sample of size 5.000. We point
out that the non-conjugate parameters of the model are updated adaptively only
after the first 1.000 iterations, serving as initial burn-in for the computation of the
adaptive quantities.
We first assess the model performance by studying the posterior distribution
of σ2 . The three panels in the first column of Figure 1, reporting the posterior
medians of σ2 for the different simulation settings, do not show noticeable differ-
ences, indicating that the choice of the interaction term used in the simulations
does not affect the estimation of σ2 . Not surprisingly, by increasing the number of
replicates in the model, the posterior estimates of all the scenarios approach the
true values used in the simulations. However, the choice of the prior distribution,
as well as the hyperparameters, has a clear effect on the estimation. In particular,
the inverse-gamma prior produces more biased results with less variability, while
the half-Cauchy behaves in the opposite way. In terms of coverage, in general we
observe larger 95% posterior credibility intervals in the half-Cauchy setting that
include the true value for most of the scenarios. Coverage in the inverse-gamma
case is observed only for larger prior variances.
We assessed the ability of the model to identify the interaction term ∆ by eval-
uating the mean square error of its estimate, indicated asMSE∆ in Figure 1(b,d,f).
The IG(3, 2) case is associated with the highest MSE∆ values, in agreement with
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the biased posterior estimates of σ2 reported earlier. This result supports the choice
of a weakly informative prior. A tabular summary of these values is reported in Sup-
plementary Table 1. Of particular notice is the high robustness of the half-Cauchy
prior to the choice of the hyperparameter h. We also provide in Supplementary
Table 2 the values of MSE∆ obtained by estimating the interaction surface with
some of the most popular methods in the literature, described in Section 2.1. The
latter are computed by using the R package synergyfinder [Yadav et al., 2015].
The R package does not handle the presence of replicates, hence we averaged the
resulting surfaces when nrep > 1. Overall, the standard methods are outperformed
by the proposed model. Also, as expected, the estimated errors decrease with the
number of replicates. Finally, the t-Student case yields poorer results. We provide
additional goodness-of-fit measures in the Supplementary Materials, namely the
Log Pseudo-Marginal Likelihood (LPML) of Geisser and Eddy [1979] in Supple-
mentary Table 3, and the for the mean surface in Supplementary Table 4. The
LPML values do not vary largely between the different scenarios, maintaining the
same magnitude when different prior settings are used. A slight departure from
this consistent behaviour is observed for the IG(3, 2) case, as previously observed.
To further illustrate the adequacy of the results, we select the simulation high-
lighted in red in Supplementary Table 1, for which the interaction surface is sim-
ulated as the non-monotone ∆(3), the variability parameters σ2φ are assigned a
half-Cauchy prior HC(1), the errors are simulated from a normal distribution, and
nrep = 3. Figure 2 shows the posterior estimates of the zero-interaction and in-
teraction surfaces in comparison with the ground truth used to simulate the data.
Furthermore, Figure 3 shows the contour plots of such surfaces. It is clear from
this comparison, how the model is able to recover the main features of the surfaces
of interest.
3.3 Application to Ovarian Cancer Cell test data
We apply the proposed model to data obtained by in-vitro combination experiments
involving two ovarian cancer cell-lines, namely OVCAR8 and SKOV3 described
at https://dtp.cancer.gov/discovery_development/nci-60/. Human ovarian
adenocarcinoma (commonly known as ovarian cancer) is the seventh most com-
mon cancer diagnosed in women worldwide, and it is characterized by a five years
survival rate of only 30% for advanced tumors. Late stage diagnosis is the main
reason for the high mortality rate Reid et al. [2017], Coleman et al. [2013]. At later
stages, the tumor presents an invasion of a tumor-triggered inflammatory fluid,
called ascites, into the abdominal cavity. This fluid is of heterogeneous composi-
tion, including tumorigenic factors, growth factors and bioactive lipids, that can
favour the growth of the malignancy Kim et al. [2016]. In-vitro studies on cell-lines
showed a tendency to resistance of the tumor to platinum-based standard-of-care
drugs Eroukhmanoff et al. [2019]. This motivates the interest in studying the effect
of drug combinations on ovarian cancer cell cultures, in particular comparing the
11
results when ascites material is added to the culture.
The cell-lines were cultured in the presence of medium alone, or of medium
and ascites. The two drug pairs tested in these experiments were Niclosamide
and WP1066, in combination with Nilotinib. Nilotinib targets the Bcr-Abl ty-
rosin kinase and the c-Kit pathway, as well as JAK-kinases. On the other hand,
WP1066 and Niclosamide target the transcription factor STAT3 (signal transducer
and activator of transcription 3). Despite Niclosamide being commonly used for the
treatment of tapeworm, it has been used in drug re-purposing studies as STAT3
inhibitor. The different mechanisms of action of the combined drugs, acting on
the same signaling pathway but at different levels, supports the use of our model,
which is based on assumptions analogous to the Bliss independence [see Fitzgerald
et al., 2006]. For each cell-line and drug combination, an experiment with nrep = 3
replicates has been performed, testing a 6x6 matrix of drug concentrations. The
resulting viability observations are then fitted using the presented model. In par-
ticular, having observed high robustness in the simulation study, we select half-
Cauchy prior distributions with h = 1 for the variance terms in the model. We
produce posterior chains of 5.000 samples from initial chains of length 50.000, after
discarding the first half as burn-in, and by applying a thinning of 5 iterations to
the second half.
3.4 Analysis of the monotherapy responses
One of the advantages of our model is the ability to perform joint inference on
different parameters of interest. We begin with a description of some measures
related to the monotherapy behaviour of the combined drugs (i.e., at the margins
of the matrix of concentrations). Figure 4 shows the posterior distribution of the
DSS, computed for each of the drugs employed in the combination experiments.
The figure is divided into two rows, one for each experimental condition (medium
and ascites or medium alone), while within each row, we show a sub-figure for each
drug tested. Regardless of the combination experiment considered, it is striking to
notice how the compounds are more effective in the absence of ascites, support-
ing the fact that the presence of ascites in the tumor micro-environment reduces
the effectiveness of the drugs Eroukhmanoff et al. [2019]. Furthermore, by looking
at the centrality of the posterior distributions of the DSS scores, we can see that
all compounds are more effective when used on the cell-line OVCAR8 (continuous
lines) than with SKOV3 (dashed lines), which may relate to their different resis-
tance profiles. As expected, the posterior distributions relative to the DSS scores
for Nilotinib, which is the compound common to all experiments, do not show con-
siderable differences for the same experimental setting (i.e., for the same culture
and cell-line characteristics, see Figure 4(a,d)).
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3.5 Analysis of the combination responses
We present a summary of the posterior estimates of the zero-interaction and inter-
action terms by means of the relative volume under the surface (rVUS), devised
to quantify the contribution of each term of the model the to the drug combina-
tion experiment. The computation of rVUS for a given surface is schematically
described in Figure 5 and its corresponding caption. Figure 6 reports the posterior
medians and 95% credibility intervals of different rVUS, in the different experi-
mental conditions. In particular, we present the rVUS for the interaction surface,
specifying its synergistic and antagonistic components in panel (a), and the rVUS
of the total interaction versus the rVUS of the complementary mean surface (1−p)
in panel (b). The last quantity is of particular interest, as it represents an overall
measure of efficacy of the combination experiments. Both combinations for SKOV3
in medium seem quite synergistic and effective. In particular, despite recovering
the fact that the compounds are more effective in the cell-line OVCAR8, we ob-
serve higher synergy levels for combinations of SKOV3 cultured in medium. As
expected, the presence of ascites reduces the effect of the drug combination in both
cell lines, and is associated with higher levels of antagonism when compared to
the experiments with medium only. Moreover, we observe that the combination
of Nilotinib with Niclosamide is more effective in medium for both OVCAR8 and
SKOV3, while the opposite is observed when the cell lines are treated with ascites
(see Figure 6(b)).
We now focus our analysis on the experiments characterized by cells cultured
in medium alone, since these seem to be the most interesting from the point of view
of study of the interaction surfaces. Analogous results for the experiments where
ascites was dispensed are reported in Section 1.2 of the Supplementary Material.
Figure 7 shows the contour plots of the posterior mean of the surface pij for the cell-
lines OVCAR8 and SKOV3, for both combinations. We can appreciate the good
fitting of the model in all the scenarios, with values of LPML in panels (a,b,c,d)
equal to 159.626, 152.862, 104.170 and 99.351, respectively. In order to characterize
the behaviour of the selected combinations, we can define:
bi-EC50(δ) := {(x, y) ∈ R2|p(x, y) ∈ (0.5± δ)}, δ > 0, (5)
representing the set of log10-concentrations for which the surface p(x, y) takes values
in a small neighbourhood of 0.5. This quantity, interpretable as a bi-variate EC50
set, can be estimated from the MCMC sample by inverting the posterior mean
pˆij , computed as Monte Carlo average. Thus, it can be very useful due to its
interpretation, especially when communicating with biomedical researchers, who
are very familiar with the concept of EC50 in the univariate case. To the best of
our knowledge, this quantity has not been proposed in the literature before, and
its computation is an advantage of the joint Bayesian modelling approach. Figure
7 reports the bi-EC50(δ) sets in log10-scale as a red dots, for δ = 0.01. The the
red points identify regions of clinical relevance, where it is expected to find a good
efficacy/toxicity trade-off.
13
As far as the zero-interaction and interaction surfaces are concerned, we re-
port similar contour plots in Figures 8 and 9, once again focusing our analysis on
the experiments where only medium was dispensed. The posterior estimates of
the zero-interaction surface shown in Figure 8 present similar behaviour for each
cell-line, indicating that the presence of Nilotinib (the common drug in all the ex-
periments) might be the driver of the response when the two compounds do not
interact, deducible from the steep decay on that side of the surface. However,
differences can be observed when looking at the interaction surfaces of Figure 9.
In particular, the posterior estimates of the interaction surface for the cell-line
SKOV3 show different behaviours for concentrations of Nilotinib around its esti-
mated EC50 (posterior mean, magenta triangle), indicating that some synergy can
be found when combined with Niclosamide. Specifically, concentrations of Nilo-
tinib slightly lower than its EC50, induce synergistic interactions with Niclosamide
around its EC50 concentration.
4 Conclusions
Drug sensitivity screening is an important component in determining personalized
therapies for cancer patients, and the practice of screening multiple compounds
at a time is becoming increasingly relevant, since combination therapies are often
preferred over treatment by individual drugs. If synergistic, drugs combinations
can help reducing the individual dosage, thereby decreasing the risk of intolerable
side effects. In addition, if the drugs have different mechanisms of action, they can
decrease the likelihood that the tumor develops drug resistance. The availability
of suitable technology, small molecule targeting compounds, and organic material,
makes this task a feasible goal.
In this work, we provided a probabilistic interpretation of the quantities at
play in viability assay experiments, by interpreting the viable state of each cell as
the outcome of a Bernoulli experiment. We model the probability of success in
order to distinguish between the zero-interaction and an interaction term. In the
proposed Bayesian setting, the use of splines as generalised covariates allows the
interaction term to present both synergistic and antagonistic features in the same
combination study. This novel approach to the study of drug-drug interaction yields
high flexibility, interpretability of the zero-interaction and interaction components,
as well as the quantification of the uncertainty of the estimates.
We provided an extensive simulation study, highlighting the importance of
the choice of the prior distributions for the model parameters. In the proposed
study, the choice of vague prior distributions seemed to be able to mitigate the
low number of replicates available. A comparison with standard approaches to
calculate measures of drug interaction (Loewe, Bliss, ZIP and HSA scores) to the
same datasets showed higher performance of the proposed method in terms of
goodness-of-fit and MSE measures.
As an application to real life data, we fit the proposed model to an ovarian
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cancer dataset produced by in-vitro experiments in Eroukhmanoff et al. [2019],
presenting various experimental conditions for two drug combinations. Namely,
the ovarian cancer cell-lines OVCAR8 and SKOV3, cultured in medium alone or
in medium and ascites (a fluid present in the abdominal cavity at later stages of
the tumor progression), are exposed to the effect of the combination of Nilotinib
and WP1066 or of Nilotinib and Niclosamide. These are compounds targeting
small molecules along the same cell pathways, and already used for the treatment
of other malignancies. In particular, we observe how the combination of drugs is
more advantageous for fighting the malignancy in case of the cell line SKOV3, with
some interaction found in the combination of Nilotinib with Niclosamide. On the
other hand, the presence of ascites seems to counter-act the effect of the drugs at
the given concentrations in all scenarios, already at the single drug level. This may
be due to the very high levels of IL-6 in the ascites, which may override the effect
of the inhibitors (in the cultures in medium there is some IL-6 secreted by the cell
lines, but much less).
The proposed approach can be extended to accommodate different prior set-
tings for the parameters. Of particular interest is the study of the prior distribution
of the variances of the parameters, which can be specified to incorporate prior in-
formation (e.g., from clinicians and experts) or to be covariate-dependent (e.g., by
including heteroscedasticity in the model). Further work concerns the possibility
of extending the model, allowing the joint analysis of different combinations at a
time, e.g. by formulating a joint hierarchical model, where appropriate hyper-prior
distributions allow borrowing of information across the different drug combina-
tions. Finally, note that while we specified our model for cell viability assays in
this manuscript, it can be easily adapted to other cell counting assays such as
cytotoxicity assays, measuring the counts of dead cells in the experiment.
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Figure 1: (a,c,e): Posterior medians and 95% posterior credibility intervals
(crossing lines) of σ2 . (b,d,f): MSE∆ (log) (dashed lines indicate the iden-
tity). Each row refers to a different interaction term. The colour estimates
are organised by pairing the prior distributions used, half-Cauchy with hy-
perparameter h (HC(h)), or inverse-gamma with identical shape and rate
parameters α (IG(α)). The intensity of the colour and the size of the dots
increase with nrep. Circles indicate scenarios with rij ∼ N(pij, σ2 ), trian-
gles with rij ∼ t5(pij, σ2 ). The black symbols (circles or triangles) in (a,c,e)
correspond to the true values of σ2 .
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(a) p0 and ∆ (b) p
(c) pˆ0 and ∆ˆ (d) pˆ
Figure 2: Simulation study: (∆(3), σ2φ ∼ HC(1), rij ∼ N(pij, σ2 ), nrep = 3).
(a,b): True surfaces. (c,d): Estimated surfaces and simulated data. The
zero-interaction surfaces are depicted in green, while the interaction surfaces
in orange. The red surfaces represent the mean surface and its estimates.
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Figure 3: Simulation study: (∆(3), σ2φ ∼ HC(1), rij ∼ N(pij, σ2 ), nrep = 3).
Contour plots of simulated (left column) versus estimated (right column)
surfaces (zero-interaction p0ij, interaction ∆ij, and mean pij).
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Figure 4: Application to Ovarian Cancer data – Posterior distribution of the
drug sensitivity scores (DSS) for the single drugs, under different experimen-
tal settings. The curves are obtained obtained via kernel-density estimation
from the MCMC posterior samples of the DSS scores. Top row: medium and
ascites; bottom row: medium alone. Continuous lines refer to the cell-line
OVCAR8, while dashed lines to the cell-line SKOV3. The number of curves
for Nilotinib is double, since this drug is present in every experiment.
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(a) p0 (b) |∆|
Figure 5: Illustration of the computation of the relative volume under the
surface (rVUS) – This quantity is computed as the ratio between the volume
under a given surface S and that of the cube limited by the support of S (grey
shapes in the figures above). The limits of the shape depend on the surface
being analysed: the zero-interaction p0 takes values in the range (0, 1) (a),
while the total interaction surface |∆| takes values in (0,maxij(p0ij, 1− p0ij)),
due to the model constraints (b). Throughout the paper, we also consider
rVUS(∆+) = rVUS(|min(0,∆)|) and rVUS(∆−) = rVUS(max(0,∆)) as the
synergistic and antagonistic contributions to the total interaction volume,
respectively. The computation of the volume under a surface S is obtained
by applying the trapezoid method along each dimension in succession.
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Figure 6: Application to Ovarian Cancer data – (a): Posterior estimates
and 95% credible intervals for the relative volume under the interaction
surface, distinguishing between synergistic (rVUS(∆+)) and antagonistic
(rVUS(∆−)) components. (b): Posterior estimates and 95% credible inter-
vals for the total relative volume under the interaction surface (rVUS(|∆|))
VS the relative volume under the complementary mean surface (rVUS(1−p)).
In both panels, black markers indicate that ascites fluid was dispensed.
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Figure 7: Application to Ovarian Cancer data – Contour plots of the pos-
terior mean of the surface pij, including the bi-EC50(0.01) estimates as red
dots, and the monotherapy EC50 estimates as magenta triangles. Experi-
ments with cell-lines treated in medium alone. Top row: OVCAR8 ; bottom
row: SKOV3. In order to obtain more self-explaining plots, the grid of con-
centrations used was extended between the observed values x1,1:n1 and x2,1:n2 ,
i.e. excluding the zero-concentrations.
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Figure 8: Application to Ovarian Cancer data – Contour plots of the pos-
terior mean of the zero-interaction surface p0ij, including the monotherapy
EC50 estimates as magenta triangles. Experiments with cell-lines treated in
medium alone. Top row: OVCAR8 ; bottom row: SKOV3.
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Figure 9: Application to Ovarian Cancer data – Contour plots of the posterior
mean of the interaction surface ∆ij, including the monotherapy EC50 esti-
mates as magenta triangles. Experiments with cell-lines treated in medium
alone. Top row: OVCAR8 ; bottom row: SKOV3.
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Supplementary Materials
The Supplementary Materials file:
Cremaschi_Frigessi_Tasken_Zucknick_Bayes_Synergy_Suppl.pdf
referenced throughout the manuscript is made available with this paper.
The zip folder:
Cremaschi_Frigessi_Tasken_Zucknick_Bayes_Synergy_Code.zip
contains the Matlab codes used in the simulated examples of Section 3.2.
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1.1 Simulation Study: additional results
We report in this section some additional results concerning the wide simu-
lation study presented in Section 3.2 of the main text. We report the tabular
version of Figure 1 in Supplementary Table 1, the MSE values for the in-
teraction surface estimated with standard methodologies in Supplementary
Table 2, the LPML values for all the simulation scenarios in Supplementary
Table 3, and MSE for the mean surface for all the simulation scenarios in
Supplementary Table 4.
From the point of view of the choice of the prior distribution for the
variance parameters, we observe lowest LPML values and highest errors in the
case of fixed variances (not reported here), and in the case of inverse-gamma
distribution with parameters (α, β) = (3, 2), consistently throughout the
simulations. As expected, we can observe an increment in the performance
when the number of replicates nrep increases. Interestingly, the choice of the
interaction term used in the simulations did not intensively affect the results,
supporting the decision of using a flexible object such as the tensor-product
spline in the model. However, higher sensitivity is shown when tuning the
prior distribution for the volatilities σ2φ, φ ∈ {m1,m2, γ0, γ1, γ2}, including
the one of the error terms, σ2 . More comments are reported in the main
paper, in relation to Figure 1.
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MSE
(1)
∆(1)
(10−3) nrep Bliss HSA Loewe ZIP
N(pij, σ
2
 )
1 11.387 6.717 5.1115 13.912
3 9.347 4.786 3.38 4.562
5 6.83 4.19 2.582 5.143
10 6.235 4.065 2.828 3.018
t5(pij, σ
2
 )
1 16.071 9.868 6.968 41.59
3 10.955 4.398 3.41 9.475
5 11.785 5.046 3.51 4.137
10 6.93 3.89 2.472 4.174
MSE
(2)
∆(2)
(10−3) nrep Bliss HSA Loewe ZIP
N(pij, σ
2
 )
1 11.416 6.572 4.9863 15.55
3 9.403 4.647 3.324 8.528
5 6.837 3.994 2.544 9.018
10 6.253 3.887 2.823 7.39
t5(pij, σ
2
 )
1 16.065 9.709 6.822 43.78
3 10.97 4.21 3.226 11.653
5 11.89 4.984 3.649 5.86
10 6.974 3.76 2.515 5.143
MSE
(3)
∆(3)
(10−3) nrep Bliss HSA Loewe ZIP
N(pij, σ
2
 )
1 14.568 7.002 5.472 31.295
3 12.928 5.253 4.27 25.02
5 10.13 4.278 3.442 23.083
10 9.151 4.046 3.558 26.565
t5(pij, σ
2
 )
1 18.869 10.069 7.186 70.809
3 15.68 5.196 4.317 33.763
5 16.867 6.317 5.591 25.662
10 10.322 4.061 3.403 24.332
Table 2: Mean square errors errors with respect to the interaction terms for stan-
dard methods.
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1.2 Ovarian cancer cell test data: experiements with
ascites
We present in this section the results of the analysis of the ovarian cancer
dataset for those experiments where both medium and ascites were dispensed.
As shown in Section 3.5 of the main text, we report the contour plots of the
posterior estimates of the mean response surface pij in Supplementary Figure
1, the zero-interaction surface p0ij in Supplementary Figure 2, and the inter-
action surface ∆ij in Supplementary Figure 3. Each plot is composed of four
panels, one for each combination/cell-line tested. The results show generally
flat response surfaces, dominated by the contribution of the zero-interactions
p0ij. However, we can observe a decrease in the estimated response surfaces for
the combination experiments involving cell-line OVCAR8 (top row in Sup-
plementary Figure 1). In particular, the model is able to estimate the EC50
of the drug WP1066 within the observed range of concentrations. These re-
sults are confirmed when looking at the interaction surfaces ∆ij, presenting
negative areas for high concentrations of WP1066 or Nilotinib.
7
-3 -2.5 -2 -1.5 -1 -0.5 0 0.5 1 1.5
WP1066 (log10 nM)
-3
-2.5
-2
-1.5
-1
-0.5
0
0.5
1
1.5
N
ilo
tin
ib
 (lo
g 1
0 
n
M
)
pˆij(x1,x2)
0
0.2
0.4
0.6
0.8
1
(a) OVCAR8
-3 -2.5 -2 -1.5 -1 -0.5 0 0.5 1
Niclosamide (log10 nM)
-3
-2.5
-2
-1.5
-1
-0.5
0
0.5
1
1.5
N
ilo
tin
ib
 (lo
g 1
0 
n
M
)
pˆij(x1,x2)
0
0.2
0.4
0.6
0.8
1
(b) OVCAR8
-3 -2.5 -2 -1.5 -1 -0.5 0 0.5 1 1.5
WP1066 (log10 nM)
-3
-2.5
-2
-1.5
-1
-0.5
0
0.5
1
1.5
N
ilo
tin
ib
 (lo
g 1
0 
n
M
)
pˆij(x1,x2)
0
0.2
0.4
0.6
0.8
1
(c) SKOV3
-3 -2.5 -2 -1.5 -1 -0.5 0 0.5 1
Niclosamide (log10 nM)
-3
-2.5
-2
-1.5
-1
-0.5
0
0.5
1
1.5
N
ilo
tin
ib
 (lo
g 1
0 
n
M
)
pˆij(x1,x2)
0
0.2
0.4
0.6
0.8
1
(d) SKOV3
Figure 1: Application to Ovarian Cancer data – Contour plots of the posterior
mean of the surface pij, including the bi-EC50(0.01) estimates as red dots,
and the monotherapy EC50 estimates as magenta triangles. The triangles
are not visible when the estimated EC50’s are outside the considered range
of concentrations. Experiments with cell-lines treated in medium and ascites.
Top row: OVCAR8 ; bottom row: SKOV3.
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Figure 2: Application to Ovarian Cancer data – Contour plots of the pos-
terior mean of the zero-interaction surface p0ij, including the monotherapy
EC50 estimates as magenta triangles. The triangles are not visible when the
estimated EC50’s are outside the considered range of concentrations. Exper-
iments with cell-lines treated in medium and ascites. Top row: OVCAR8 ;
bottom row: SKOV3.
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Figure 3: Application to Ovarian Cancer data – Contour plots of the posterior
mean of the interaction surface ∆ij, including the monotherapy EC50 esti-
mates as magenta triangles. The triangles are not visible when the estimated
EC50’s are outside the considered range of concentrations. Experiments with
cell-lines treated in medium and ascites. Top row: OVCAR8 ; bottom row:
SKOV3.
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2 MCMC Algorithm
As introduced in the main text, we resort to Metropolis-Hastings type up-
dates in throughout the MCMC posterior sampling, since most of the param-
eters involved in this study are not conjugate to the model. In particular,
to ensure faster convergence and good mixing properties of the posterior
MCMC chains, we use adaptive algorithms Griffin and Stephens [2013]. The
main idea at the basis of such algorithms is to re-calculates the parameters
of the proposal distributions using the MCMC samples previously produced
by the sampling process. Let θ ∈ Θ, with Θ ⊂ Rd, be a random vector of
dimension d, and suppose we want to sample from its posterior distribution
with probability density function p(θ|y) ∝ f(y|θ)pi(θ). As usual, we refer to
f(y|θ) and pi(θ) as the likelihood and prior distribution, respectively. First,
we consider a transformation t : Θ→ Rd, such that t(θ) has full support on
Rd. If Θ = Rd, then we resort to the identity transformation t(θ) = θ. At
the g-th iteration of the algorithm, we propose a new value θ∗ such that:
t(θ∗) = t(θ(g)) + ,  ∼ N(t(θ(g)), ξ(g)) (1)
and accept θ(g+1) = θ∗ with probability:
a(θ∗,θ(g)) = min
(
1,
p(θ∗|y)
p(θ(g)|y)
|Jt(θ(g))|
|Jt(θ∗)|
)
, (2)
where |Jt(θ)| denotes the determinant of the Jacobian of the transforma-
tion t evaluated at θ. After an initial number g0 of standard (i.e., non-
adaptive) Metropolis-Hastings steps (g0 = 1.000 in the simulations), the
algorithm updates the covariance matrix of the random walk proposal, for
which ξ(g+1) ≡ ξ(0), in this way:
ξ(g+1) =
s(g+1)
g − 1
 g∑
g′=1
tg′tg′
> − 1
g
(
g∑
g′=1
tg′
)(
g∑
g′=1
tg′
)>+ s(g+1)Id
where tg ≡ t(θ(g)), x> denotes the transposed of the vector x, and Id de-
notes the d-dimensional identity matrix. The magnitude of the adaptation is
determined by the quantity s(g+1), which is tuned via the acceptance prob-
ability a(θ∗,θ(g)) at each iteration. Further details can be found in [Griffin
and Stephens, 2013]. We use this approach within a Gibbs sampling scheme
to update the parameters of the proposed model. In the following section,
we provide the detailed expressions of the full-conditionals distributions used
in MCMC algorithm.
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2.1 Additional details
Let f(y|θ) denote the likelihood distribution for the proposed model, which
in the proposed model corresponds to:
f(y|p, σ2 ) =
n1∏
i=0
n2∏
j=0
nrep∏
r=0
N(yrij|pij, σ2 ), (3)
where we address the reader to formulas (4) in the main manuscript for the
expression of the mean parameter pij. However, details on the parts that
are modified in each proposal step are highlighted in the following part. In
what follows, N and Nd represents a univariate and a d-variate Gaussian
distribution, respectively.
• Update m1 (analogously for m2): propose m∗1 ∼ N(m(g)1 , ξ(g)m1) and ac-
cept with probability (2), where |Jt(x)| = 1 for x = m(g)1 ,m∗1, and:
p0∗ij = f(x1i|m∗1, λ1)f(x2j|m2, λ),
p∗ij = p
0∗
ij + ∆ij,
for i = 0, . . . , n1 and j = 0, . . . , n2. Including the likelihood and the
prior distribution, we obtain the acceptance ratio:
a(m∗1,m
(g)
1 ) =
f(y|p∗, σ2 )
f(y|p, σ2 )
e
− 1
2σ2m1
(
(m∗1)
2−(m(g)1 )2
)
• Update λ1 (analogously for λ2): propose log(λ∗1) ∼ N(log(λ(g)1 ), ξ(g)λ1 )
and accept with probability (2), where |Jt(x)| = x−1 for x = λ(g)1 , λ∗1,
and:
p0∗ij = f(x1i|m1, λ∗1)f(x2j|m2, λ),
p∗ij = p
0∗
ij + ∆ij,
for i = 0, . . . , n1 and j = 0, . . . , n2. Including the likelihood and the
prior distribution, we obtain the acceptance ratio:
a(λ∗1, λ
(g)
1 ) =
f(y|p∗, σ2 )
f(y|p, σ2 )
(
λ∗1
λ
(g)
1
)αλ1
e−βλ1 (λ
∗
1−λ(g)1 ).
• Update b = (b1, b2) (jointly): propose log(b∗) ∼ N2(log(b), ξ(g)b ) and
accept with probability (2), where |Jt(x)| =
∏
x−1 for x = b, b∗, and:
g∗(Bij) = −p0ij(1 + eb
∗
1Bij)−1 + (1− p0ij)(1 + e−b
∗
2Bij)−1,
∆∗ij = g
∗(Bij)I{i,j>0}(Bij),
p∗ij = p
0
ij + ∆
∗
ij,
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for i = 0, . . . , n1 and j = 0, . . . , n2. Including the likelihood and the
prior distribution, we obtain the acceptance ratio:
a(b∗, b(g)) =
f(y|p∗, σ2 )
f(y|p, σ2 )
(
b∗1
b
(g)
1
)αb1 (
b∗2
b
(g)
2
)αb2
e−βb1 (b
∗
1−b(g)1 )−βb2 (b∗2−b
(g)
2 ).
• Update γ0 (analogously for γ1 and γ2):
propose log(γ∗0) ∼ N(log(γ(g)0 ), ξ(g)γ0 ) and accept with probability (2),
where |Jt(x)| = x−1 for x = γ(g)0 , γ∗0 , and:
B∗ij = γ
∗
0 + γ1x1i + γ2x2j +B(x1i, x2j),
g(B∗ij) = −p0ij(1 + eb1B
∗
ij)−1 + (1− p0ij)(1 + e−b2B
∗
ij)−1,
∆∗ij = g(B
∗
ij)I{i,j>0}(B∗ij),
p∗ij = p
0
ij + ∆
∗
ij,
for i = 0, . . . , n1 and j = 0, . . . , n2. Including the likelihood and the
prior distribution, we obtain the acceptance ratio:
a(γ∗0 , γ
(g)
0 ) =
f(y|p∗, σ2 )
f(y|p, σ2 )
e
− 1
2σ2γ0
(
(γ∗0 )
2−(γ(g)0 )2
)
.
• Update C (jointly): propose C∗ ∼ NK1K2(vec(C(g)), ξ(g)C ) and accept
with probability (2), where |Jt(x)| =
∏
x−1 for x = C(g),C∗, and:
B∗(x1i, x2j) =
∑
l,m
C∗lmBl(x1i)Bm(x2j),
B∗ij = γ0 + γ1x1i + γ2x2j +B
∗(x1i, x2j),
g(B∗ij) = −p0ij(1 + eb1B
∗
ij)−1 + (1− p0ij)(1 + e−b2B
∗
ij)−1,
∆∗ij = g(B
∗
ij)I{i,j>0}(B∗ij),
p∗ij = p
0
ij + ∆
∗
ij,
for i = 0, . . . , n1 and j = 0, . . . , n2. Including the likelihood and the
prior distribution, we obtain the acceptance ratio:
a(C∗,C(g)) =
f(y|p∗, σ2 )
f(y|p, σ2 )
e−
1
2(tr(Ψ
−1
1 (C
∗)>Ψ−12 C
∗)−tr(Ψ−11 (C(g))>Ψ−12 C(g)))).
• Update σ2φ, φ ∈ {m1,m2, γ0, γ1, γ2}. This step depends on the choice
of the prior distribution, that in this work is chosen to be either a
half-Cauchy(h), for h > 0, or an inverse-Gamma IG(α, β).
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HC(h) Propose log(σ∗φ) ∼ N(log(σ(g)φ ), ξ(g)σφ ) and accept with probability
(2), where |Jt(x)| = x−1 for x = σ(g)φ , σ∗φ, and we obtain the
acceptance ratio:
a(σ∗φ, σ
(g)
φ ) = e
−φ2
2
(
1
(σ∗
φ
)2
− 1
(σ
(g)
φ
)2
)
(σ
(g)
φ )
2 + h2
(σ∗φ)2 + h2
.
IG(α, β) The conjugate sampler has full conditional:
p(σφ|y,θ) ∼ IG(αφ, βφ),
αφ = α +
1
2
,
βφ = β +
1
2
φ2.
• Update σ2 . This step depends on the choice of the prior distribution,
that in this work is chosen to be either a half-Cauchy(h), for h > 0, or
an inverse-Gamma IG(α, β).
HC(h) Propose log(σ∗ ) ∼ N(log(σ(g) ), ξ(g)σ2 ) and accept with probability
(2), where |Jt(x)| = x−1 for x = σ(g) , σ∗ , and we obtain the ac-
ceptance ratio:
a(σ∗ , σ
(g)
 ) =(
(σ∗ )
2
(σ
(g)
 )2
)(1−nrepn1n2)/2
e
− ∑
i,j,r
(yrij−pij)2
2
(
1
(σ∗ )2
− 1
(σ
(g)
 )
2
)
(σ
(g)
 )2 + h2
(σ∗ )2 + h2
.
IG(α, β) The conjugate sampler has full conditional:
p(σ|y,θ) ∼ IG(α, β),
α = α +
nrepn1n2
2
,
β = β +
1
2
∑
i,j,r
(yrij − pij)2.
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